FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Myanmar has faced substantial disruption, with impacts on respiratory health, in the aftermath of a devastating 7·7 magnitude earthquake. The country was hit on March 28, 2025, along with its ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Many power plants benefiting from exemptions rank among the nation’s worst polluters. The Trump administration says cheaper ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

There is significant risk for subsequent stroke in patients hospitalized for acute exacerbation of COPD with atrial fibrillation.

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.